Sathirakul Korbtham, Chan Clark, Teng Leyan, Bergstrom Richard F, Yeo Kwee Poo, Wise Stephen D
Lilly-NUS Centre for Clinical Pharmacology, National University of Singapore, Singapore.
Br J Clin Pharmacol. 2003 Aug;56(2):184-7. doi: 10.1046/j.1365-2125.2003.01857.x.
To compare the pharmacokinetic profiles and dose proportionality of olanzapine in Chinese and Caucasian subjects.
Randomized, three-period study with 12 Chinese and 12 Caucasian, healthy, male subjects administered 2.5, 5 and 10 mg olanzapine. Noncompartmental pharmacokinetic parameters were derived.
No statistically significant racial differences in the weight-normalized pharmacokinetic parameters were observed except for Vz/Fnorm, which was 17% lower at the 5- and 10-mg dose in the Chinese group (95% confidence interval 8.49, 10.1 and 8.05, 9.73, respectively), compared with the Caucasian group (9.53, 12.8 and 9.39, 12.0, respectively). Olanzapine's pharmacokinetics were linear and dose proportional in both racial groups.
The pharmacokinetics of olanzapine are similar in both Chinese and Caucasian racial groups.
比较奥氮平在中国受试者和高加索受试者中的药代动力学特征及剂量比例关系。
采用随机、三周期研究,12名中国健康男性受试者和12名高加索健康男性受试者服用2.5、5和10毫克奥氮平。得出非房室药代动力学参数。
除Vz/Fnorm外,体重标准化药代动力学参数未观察到统计学上的显著种族差异。中国组在5毫克和10毫克剂量时,Vz/Fnorm分别比高加索组低17%(95%置信区间分别为8.49, 10.1和8.05, 9.73),而高加索组分别为9.53, 12.8和9.39, 12.0。奥氮平在两个种族组中的药代动力学均呈线性且与剂量成比例。
奥氮平在中国种族组和高加索种族组中的药代动力学相似。